{"filing":{"accession_number":"0001104659-26-110412","cik":"0001509261","ticker":"RZLT","company_name":"Rezolute, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"tm2625842d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_8k.htm"},"events":[{"id":34900,"run_id":32135,"accession_number":"0001104659-26-110412","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Rezolute's financial results for the fourth quarter and full fiscal year ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its financial results\" with condensed consolidated financial statements showing R\u0026D expenses, G\u0026A expenses, net loss, and balance sheet data. The press release is attached as Exhibit 99.1 and includes both financial results and a business update on clinical trial progress.","company_name":"Rezolute, Inc.","ticker":"RZLT","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38769,"accession_number":"0001104659-26-110412","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Rezolute's financial results for the fourth quarter and full fiscal year ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its financial results\" with condensed consolidated financial statements showing R\u0026D expenses, G\u0026A expenses, net loss, and balance sheet data. The press release is attached as Exhibit 99.1 and includes both financial results and a business update on clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:20:39.665450+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38769,"accession_number":"0001104659-26-110412","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Rezolute's financial results for the fourth quarter and full fiscal year ended June 30, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its financial results\" with condensed consolidated financial statements showing R\u0026D expenses, G\u0026A expenses, net loss, and balance sheet data. The press release is attached as Exhibit 99.1 and includes both financial results and a business update on clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:20:39.665450+00:00","company_name":"Rezolute, Inc.","ticker":"RZLT","filing_date":"2026-09-24"}]}